P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells

P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhibitor Ensartinib in Cancer Cells

Ensartinib (X-396) is a promising second-generation small-molecule inhibitor of anaplastic lymphoma kinase (ALK) that was developed for the treatment of ALK-positive non-small-cell lung cancer. Preclinical and clinical trial results for ensartinib showed superior efficacy and a favorable safety prof...

Full description

Bibliographic Details
Main Authors: Chung-Pu Wu, Cheng-Yu Hung, Megumi Murakami, Yu-Shan Wu, Chun-Ling Lin, Yang-Hui Huang, Tai-Ho Hung, Jau-Song Yu, Suresh V. Ambudkar
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Cancers
Subjects:
P-glycoprotein
multidrug resistance
ALK
ensartinib
X-396
Online Access:https://www.mdpi.com/2072-6694/14/9/2341

Internet

https://www.mdpi.com/2072-6694/14/9/2341

Similar Items